SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/263422"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/263422" > Lysyl oxidase and a...

Lysyl oxidase and adipose tissue dysfunction

Pastel, E. (författare)
Price, E. (författare)
Sjöholm, Kajsa, 1971 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
visa fler...
McCulloch, L. J. (författare)
Rittig, N. (författare)
Liversedge, N. (författare)
Knight, B. (författare)
Moller, N. (författare)
Svensson, Per-Arne, 1969 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Kos, K. (författare)
visa färre...
 (creator_code:org_t)
Elsevier BV, 2018
2018
Engelska.
Ingår i: Metabolism - Clinical and Experimental. - : Elsevier BV. - 0026-0495. ; 78, s. 118-127
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background/objectives. Lysyl oxidase (LOX) is an enzyme crucial for collagen fibre crosslinking and thus for fibrosis development. Fibrosis is characterised by a surplus of collagen fibre accumulation and is amongst others also a feature of obesity-associated dysfunctional adipose tissue (AT) which has been linked with type 2 diabetes. We hypothesised that in type 2 diabetes and obesity LOX expression and activity will be increased as a consequence of worsening AT dysfunction. This study aimed to provide a comprehensive characterisation of LOX in human AT. Methods. LOX mRNA expression was analysed in omental and abdominal subcutaneous AT obtained during elective surgery from subjects with a wide range of BMI, with and without diabetes. In addition, LOX expression was studied in subcutaneous AT before and 9.5 months after bariatric surgery. To study the mechanism of LOX changes, its expression and activity were assessed after either hypoxia, recombinant human leptin or glucose treatment of AT explants. In addition, LOX response to acute inflammation was tested after stimulation by a single injection of lipopolysaccharide versus saline solution (control) in healthy men, in vivo. Quantity of mRNA was measured by RT-qPCR. Results. LOX expression was higher in obesity and correlated with BMI whilst, in vitro, leptin at high concentrations, as a potential feedback mechanism, suppressed its expression. Neither diabetes status, nor hyperglycaemia affected LOX. Hypoxia and lipopolysaccharide-induced acute inflammation increased LOX AT expression, latter was independent of macrophage infiltration. Conclusions. Whilst LOX may not be affected by obesity-associated complications such as diabetes, our results confirm that LOX is increased by hypoxia and inflammation as underlying mechanism for its upregulation in adipose tissue with obesity. (C) 2017 Elsevier Inc. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Obesity
Fibrosis
Diabetes
Bariatric surgery
Inflammation
extracellular-matrix
insulin-resistance
metabolic profile
liver
fibrosis
weight-loss
obesity
hypoxia
expression
macrophages
adipocytes
Endocrinology & Metabolism

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy